TNFRSF10A and colorectal carcinoma: The availability of 220 CRC from affected individuals who had undergone adjuvant therapy: chemotherapy and/or radiotherapy, allowed us to investigate the possible impact of TRAIL-R1 on response to adjuvant therapy.